HUP0400405A2 - Pirimidinszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik - Google Patents
Pirimidinszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeikInfo
- Publication number
- HUP0400405A2 HUP0400405A2 HU0400405A HUP0400405A HUP0400405A2 HU P0400405 A2 HUP0400405 A2 HU P0400405A2 HU 0400405 A HU0400405 A HU 0400405A HU P0400405 A HUP0400405 A HU P0400405A HU P0400405 A2 HUP0400405 A2 HU P0400405A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- alkyl group
- optionally substituted
- hydrogen atom
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 methylenedioxyphenyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Jelen találmány az oxerin receptor antagonista (I) általános képletűvegyületekre ahol X jelentése C1-4-alkilcsoport, adott esetbenhelyettesített aminocsoport, C1-4-alkil-S-csoport, telített vagyrészben telített mono- vagy biciklus, amely 1 vagy 2 vagy 3heteroatomot (N, O vagy S) tartalmazhat és nitrogénatomon keresztülkapcsolódik a pirimidin-gyűrűhöz, Ar jelentése fenilcsoport, 1-3azonos vagy eltérő heteroatomot tartalmazó 5 vagy 6 tagú heterociklusvagy metiléndioxifenil-csoport, mely csoportok adott esetbenhelyettesítve lehetnek; R jelentése hidrogénatom vagy C1-4-alkilcsoport; Y jelentése hidrogénatom vagy C1-4-alkilcsoport; Wjelentése hidrogénatom vagy C1-4-alkilcsoport; Z jelentésehidroxilcsoport, halogénatom, C1-4-alkoxicsoport, aminocsoport, Cl-4-alkil-amino-csoport, -NHCOC1-4-alkilcsoport, vagy R+Y együttesjelentése a közbezárt nitrogén és szénatommal együtt Z+W együttesjelentése oxocsoport; Q jelentése 1-3 azonos vagy eltérő heteroatomottartalmazó 5 vagy 6 tagú heterociklus, mely adott esetben egy vagytöbb azonos vagy különböző C1-4-alkil-, C1-4-alkoxicsoporttal,hidroxilcsoporttal vagy halogénatommal helyettesítve van, vagy -sóikra, izomerjeikre és szolvátjaikra vonatkozik.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0400405A HUP0400405A3 (en) | 2004-02-10 | 2004-02-10 | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
JP2006552698A JP4825686B2 (ja) | 2004-02-10 | 2005-02-08 | オレキシン受容体アンタゴニストとしてのピリミジン誘導体 |
EP05708501A EP1718632B1 (en) | 2004-02-10 | 2005-02-08 | Pyrimidine derivatives as orexin receptor antagonists |
DE602005014086T DE602005014086D1 (de) | 2004-02-10 | 2005-02-08 | Pyrimidinderivate als orexin-rezeptorantagonisten |
PCT/HU2005/000010 WO2005075458A1 (en) | 2004-02-10 | 2005-02-08 | Pyrimidine derivatives as orexin receptors antagonists |
AT05708501T ATE429427T1 (de) | 2004-02-10 | 2005-02-08 | Pyrimidinderivate als orexin-rezeptorantagonisten |
US11/463,825 US7812031B2 (en) | 2004-02-10 | 2006-08-10 | Pyrimidine derivatives as orexin receptor antagonists |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0400405A HUP0400405A3 (en) | 2004-02-10 | 2004-02-10 | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0400405D0 HU0400405D0 (en) | 2004-04-28 |
HUP0400405A2 true HUP0400405A2 (hu) | 2005-09-28 |
HUP0400405A3 HUP0400405A3 (en) | 2009-03-30 |
Family
ID=89981980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400405A HUP0400405A3 (en) | 2004-02-10 | 2004-02-10 | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
Country Status (7)
Country | Link |
---|---|
US (1) | US7812031B2 (hu) |
EP (1) | EP1718632B1 (hu) |
JP (1) | JP4825686B2 (hu) |
AT (1) | ATE429427T1 (hu) |
DE (1) | DE602005014086D1 (hu) |
HU (1) | HUP0400405A3 (hu) |
WO (1) | WO2005075458A1 (hu) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
FR2896799B1 (fr) * | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
GB0614579D0 (en) * | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
US20080287452A1 (en) * | 2007-05-16 | 2008-11-20 | Wyeth | Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
US8242121B2 (en) | 2007-05-23 | 2012-08-14 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
GB0712888D0 (en) * | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR20100061486A (ko) * | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
EP2214676B1 (en) * | 2007-10-29 | 2012-11-21 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
US20110086889A1 (en) * | 2008-06-11 | 2011-04-14 | Hamed Aissaoui | Tetrazole compounds as orexin receptor antagonists |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
AU2009305005A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
US8466281B2 (en) * | 2008-10-21 | 2013-06-18 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
NZ592544A (en) * | 2008-10-30 | 2013-01-25 | Merck Sharp & Dohme | Isonicotinamide orexin receptor antagonists |
JP2012507539A (ja) * | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
PL2491038T3 (pl) | 2009-10-23 | 2016-10-31 | Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny | |
CN101955463B (zh) * | 2010-08-04 | 2012-01-04 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2708537A4 (en) * | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
KR20140124398A (ko) | 2012-02-07 | 2014-10-24 | 이올라스 테라퓨틱스, 인코포레이티드 | 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘 |
BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
US9732077B2 (en) | 2013-12-18 | 2017-08-15 | Merck Sharp & Dohme Corp. | Diazepane orexin receptor antagonists |
JP2017100950A (ja) * | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキソ複素環誘導体 |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
RS63471B1 (sr) | 2016-02-12 | 2022-08-31 | Astrazeneca Ab | Halo-supstituisani piperidini kao modulatori receptora oreksina |
HUE058759T2 (hu) | 2016-03-10 | 2022-09-28 | Janssen Pharmaceutica Nv | Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával |
WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
WO2018110580A1 (ja) | 2016-12-13 | 2018-06-21 | 三菱日立パワーシステムズ株式会社 | ガスタービンの分解組立方法、シール板組立体及びガスタービンロータ |
TWI696751B (zh) | 2016-12-13 | 2020-06-21 | 日商三菱日立電力系統股份有限公司 | 燃氣渦輪機的分解組裝方法、密封板組裝體、燃氣渦輪機輥、然氣渦輪機及燃氣渦輪機的製造方法 |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201903832D0 (en) * | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
CN112920111B (zh) * | 2019-12-06 | 2022-05-17 | 中国科学院大连化学物理研究所 | 一种多取代吡啶衍生物及其合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2835669A (en) * | 1958-05-20 | Process for the production of substi- | ||
DE244321C (hu) * | ||||
US2514380A (en) * | 1946-12-26 | 1950-07-11 | Hoffmann La Roche | Diamines and method of production |
GB1159263A (en) * | 1966-08-31 | 1969-07-23 | Smith Kline French Lab | Guanidine Derivatives and Process for Preparing the same |
US3467662A (en) * | 1967-10-05 | 1969-09-16 | Sandoz Ag | 1-para-chlorophenyl-3-hydrazino - 1,5,6,7,8,8a-hexahydroimidazo(1,5-a)pyridine and process for its preparation |
GB1270120A (en) * | 1968-11-08 | 1972-04-12 | Wander Ltd A | Pyrimidine carboxylic acid ester derivatives |
BE787617A (fr) * | 1971-08-16 | 1973-02-16 | Bristol Myers Co | Imidazolines et procede pour les preparer |
AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
US4698340A (en) * | 1984-07-19 | 1987-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine derivatives, processes for preparation thereof and composition containing the same |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
JPH07101940A (ja) * | 1993-08-13 | 1995-04-18 | Nippon Nohyaku Co Ltd | ピリミジンおよびピリジン誘導体、その製法および用途 |
US6274588B1 (en) * | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
WO2001096302A1 (en) * | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
CN100506801C (zh) * | 2000-09-06 | 2009-07-01 | 诺华疫苗和诊断公司 | 糖元合成酶激酶3的抑制剂 |
WO2002022588A1 (fr) * | 2000-09-14 | 2002-03-21 | Ajinomoto Co.,Inc. | Nouveau derive de pyrimidine et nouveau derive de pyridine |
GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0225944D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
JP2008519034A (ja) * | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
-
2004
- 2004-02-10 HU HU0400405A patent/HUP0400405A3/hu unknown
-
2005
- 2005-02-08 AT AT05708501T patent/ATE429427T1/de not_active IP Right Cessation
- 2005-02-08 EP EP05708501A patent/EP1718632B1/en not_active Not-in-force
- 2005-02-08 JP JP2006552698A patent/JP4825686B2/ja not_active Expired - Fee Related
- 2005-02-08 WO PCT/HU2005/000010 patent/WO2005075458A1/en not_active Application Discontinuation
- 2005-02-08 DE DE602005014086T patent/DE602005014086D1/de active Active
-
2006
- 2006-08-10 US US11/463,825 patent/US7812031B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1718632A1 (en) | 2006-11-08 |
US7812031B2 (en) | 2010-10-12 |
WO2005075458A8 (en) | 2006-01-19 |
HU0400405D0 (en) | 2004-04-28 |
US20070043037A1 (en) | 2007-02-22 |
ATE429427T1 (de) | 2009-05-15 |
DE602005014086D1 (de) | 2009-06-04 |
JP2007522197A (ja) | 2007-08-09 |
JP4825686B2 (ja) | 2011-11-30 |
EP1718632B1 (en) | 2009-04-22 |
HUP0400405A3 (en) | 2009-03-30 |
WO2005075458A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400405A2 (hu) | Pirimidinszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0301745A2 (hu) | Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása | |
HUP0301573A2 (hu) | Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TW200800945A (en) | Macrocylic inhibitors of hepatitis c virus | |
HUP9802865A2 (hu) | N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények | |
PL368409A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303637A2 (hu) | Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
RU2010121763A (ru) | Производные пиридазинона и ингибиторы р2х7 рецептора | |
HUP0300565A2 (hu) | PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0302893A2 (hu) | Nem-imidazol ariloxipiperidinek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
HUP0203245A2 (hu) | Foszfodiészteráz VII-inhibitorként használható imidazopiridinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
RS20050450A (en) | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | |
ATE535241T1 (de) | Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie | |
HUP0303480A2 (hu) | 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203422A2 (hu) | Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: SANOFI-AVENTIS, FR Free format text: FORMER OWNER(S): SANOFI-SYNTHELABO, FR |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |